Literature DB >> 10701623

Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer.

E F Patz1, J Connolly, J Herndon.   

Abstract

OBJECTIVE: We determined the prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for patients with treated lung cancer.
MATERIALS AND METHODS: We examined patients who underwent FDG PET after first-line treatment for non-small cell lung cancer. FDG PET results were correlated with survival rates to determine whether FDG PET findings were predictive of outcomes.
RESULTS: After initial therapy, 113 patients with non-small cell lung cancer underwent FDG PET. One hundred patients had positive FDG PET results and a median survival of 12 months (95% confidence interval, 9.2-15.4). Thirteen patients had negative FDG PET results, and 11 (85%) of these patients are still living at a median follow-up of 34 months. The difference in survival for patients with positive and negative FDG PET results was statistically significant (p = 0.002).
CONCLUSION: FDG PET has prognostic value and strongly correlates with survival rates of patients with treated lung cancer. Patients with positive FDG PET results have a significantly worse prognosis than patients with negative results. Additionally, FDG PET may be helpful in guiding therapeutic treatments.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10701623     DOI: 10.2214/ajr.174.3.1740769

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  17 in total

Review 1.  Molecular imaging for personalized cancer care.

Authors:  Moritz F Kircher; Hedvig Hricak; Steven M Larson
Journal:  Mol Oncol       Date:  2012-03-10       Impact factor: 6.603

2.  Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.

Authors:  Dirk Hellwig; Andreas Gröschel; Thomas P Graeter; Anne P Hellwig; Ursula Nestle; Hans-Joachim Schäfers; Gerhard W Sybrecht; Carl-Martin Kirsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

3.  A phase II study of radiofrequency ablation therapy for thoracic malignancies with evaluation by FDG-PET.

Authors:  Mitsunori Higuchi; Hiroshi Honjo; Takeshi Shigihara; Fumio Shishido; Hiroyuki Suzuki; Mitsukazu Gotoh
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-21       Impact factor: 4.553

4.  Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.

Authors:  Chenpeng Zhang; Chuanhong Liao; Bill C Penney; Daniel E Appelbaum; Cassie A Simon; Yonglin Pu
Journal:  Radiology       Date:  2015-01-14       Impact factor: 11.105

Review 5.  The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer.

Authors:  Sara Volpi; Jason M Ali; Angela Tasker; Adam Peryt; Giuseppe Aresu; Aman S Coonar
Journal:  Ann Transl Med       Date:  2018-03

6.  FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.

Authors:  Hyun Woo Chung; Kye Young Lee; Hee Joung Kim; Wan Seop Kim; Young So
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-06       Impact factor: 4.553

7.  Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer.

Authors:  Noah C Choi; Tristen T Chun; Andrzej Niemierko; Marek Ancukiewicz; Panos M Fidias; Richard L Kradin; Douglas J Mathisen; Thomas J Lynch; Alan J Fischman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-12       Impact factor: 9.236

Review 8.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

9.  Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy.

Authors:  Sung Ho Hwang; Mi Ri Yoo; Chul Hwan Park; Tae Joo Jeon; Sang Jin Kim; Tae Hoon Kim
Journal:  Eur Radiol       Date:  2013-01-09       Impact factor: 5.315

10.  FDG uptake at the bronchial stump after curative lobectomy for non-small cell lung cancer.

Authors:  Caroline Keyzer; Florence Corbusier; Eirini Kyratzi; Youri Sokolow; Pierre Alain Gevenois; Serge Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.